AC Immune (ACIU) said Wednesday that the US Food and Drug Administration has issued a Fast Track Designation for the PI-2620 Tau positron emission tomography, or PET, imaging agent that the company is developing with privately held Life Molecular Imaging to diagnose three neurodegenerative conditions, including Alzheimer's disease.
The Fast Track Designation also covers PI-2620 as a potential diagnostic for progressive supranuclear palsy and corticobasal degeneration, AC Immune said.
PI-2620 is in phase 3 clinical development for detecting Tau pathology in Alzheimer's disease and could eventually be adapted also for non-Alzheimer tauopathies such as progressive supranuclear palsy and corticobasal syndrome, the company said.
AC Immune rose nearly 2% in early trading Wednesday.
Price: 3.1200, Change: +0.06, Percent Change: +1.96
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.